Yikon Genomics

company

About

This company is a Genetic Tests To Support Family Planning Stages of Life.

  • 51 - 100

Details

Last Funding Type
Series D
Last Funding Money Raised
¥250M
Industries
Biotechnology,Genetics
Founded date
Jan 1, 2012
Number Of Employee
51 - 100
Operating Status
Active

Yikon Genomics is a leading solution-based single cell sequencing company. Currently based on the patented MALBAC® technology from Harvard University, Yikon provides complete solutions in the fields of reproductive health and cancer diagnostics with liquid tumor biopsy. The MALBAC-PGS™ and MALBAC-PGD™ solutions offer the most accurate and comprehensive embryo testing results for physicians to choose the best embryos with balanced chromosomal copy numbers,without inheriting the known disease-associated alleles. The MALBAC-PGS™ and MALBAC-PGD™ solutions have helped thousands of couples to achieve successful pregnancies. Yikon will continue to interpret the code of life and bring people the hope and joy of life.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
¥250M
Yikon Genomics has raised a total of ¥250M in funding over 2 rounds. Their latest funding was raised on May 6, 2021 from a Series D round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 6, 2021 Series D ¥250M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Yikon Genomics is funded by 2 investors. Zhongjin Qide and General Technology Venture Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Zhongjin Qide Series D
General Technology Venture Capital Series D